Tag Archives: molecular diagnostics

Tepid Rally Favors Large Caps: ABBV, GILD, RHHBY

Healthcare Stocks trail other sectors up 0.34%,  Energy  up 0.8%,  Financials up 0.73% and Technology up 0.77% But biotech ETFs are in the Green Biotechnology stocks were mixed today with the following winners among our large cap picks: Gilead Sciences (GILD) up 1.26%, Roche Holding (RHHBY) up 1.08% and Regeneron up 0.58%. Our large cap […]

Leave a comment Continue Reading →

Biotech Bubble has Burst-Back to Basics: ABBV, HOLX

Risk-Off -Stay With Large Caps In case you missed it the speculative frenzy in biotech stocks is over for now but there are always trading opportunities for the short and long term. We recently posted our Q1 Rayno Life Science update for biopharmaceuticals and the large cap stocks are holding up well in a choppy market. […]

Comments Off Continue Reading →

Rayno Life Science: Tools and Diagnostics Q1 2014 Performance

Caution As Life Science Stocks Are Consolidating Life science stocks had a wild roller coaster ride in 2014 with many stocks peaking around March 1. Momentum and cult stocks in our portfolio still had a good quarter with the following top winners: Illumina (ILMN) up 25.2%, Vermillion (VRML) up 25%, Exact Sciences (EXAS) up 21% […]

Comments Off Continue Reading →

Rayno Life Science Stocks Rally: Green Screen… IBB UP 2.5% Update

Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer and 42% with pre-cancerous lesions. (See detailed data). 2015 revenue forecasts from […]

Comments Off Continue Reading →

Clinical Diagnostic Companies 2013 Financial Metrics and Valuation Models

Diagnostics  Companies-After 2013 Financial Reporting Stocks to Watch: Cepheid (CPHD), Exact Sciences (EXAS) , Orasure (OSUR) Price to Sales (P/S) is the best metric of value as many companies in the sector are not profitable. Molecular diagnostics and genomics are the strongest growth sectors e.g. Cepheid (CPHD), ResponseGenetics (RGDX). Many stocks show a “topping effect” or […]

Comments Off Continue Reading →

Biotech Stocks Lagging In Today’s Rally

But A Lot of Green Today  in Diagnostics and Tools The NASDAQ (4030)and the S&P (1787) are up about 0.7%  but biotech stocks are lagging with the IBB ($216) up only 0.33%. Momentum in biopharmaceutical stocks has been easing since a late November move around the $225 mark. Stock distribution predominates in December. The IBB is […]

Comments Off Continue Reading →